BioArctic Announces Nomination Committee for 2027 Annual General Meeting
News related to:BioArctic AB · 2 min read
STOCKHOLM, October 30, 2026 /CourierPR/ -- BioArctic AB has announced the composition of its Nomination Committee for the 2027 Annual General Meeting, a critical step in the company’s governance structure. The committee, which will play a key role in recommending candidates for the Board of Directors, has been appointed in accordance with the principles adopted by the company’s Annual General Meeting.
The Nomination Committee consists of representatives from the three largest shareholders by voting rights as of September 30, 2026, along with the Chair of the Board. Specifically, the committee members are:
- Margareta Öhrvall, appointed by Demban AB - Pär Gellerfors, appointed by Ackelsta AB - Thomas Ehlin, Chair of the Nomination Committee, representing Fjärde AP-fonden
Together, these shareholders hold approximately 57 percent of the shares and 82 percent of the votes in the company. This significant shareholding ensures that the committee has a substantial influence over the direction of the company.
BioArctic’s Annual General Meeting 2027 is scheduled to be held on Thursday, May 27, 2027, at 4:30 pm CEST in Stockholm. Shareholders are encouraged to submit proposals to the Nomination Committee by January 15, 2027, to ensure their suggestions can be considered. Instructions for submitting proposals are available on BioArctic’s website at www.bioarctic.com/en/governance/nomination-committee.
The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2027, as well as on the company’s website, www.bioarctic.com. To ensure that submitted proposals can be considered by the Nomination Committee, they should be received no later than January 15, 2027.
BioArctic AB is a Swedish research-based biopharma company focused on developing innovative treatments for neurodegenerative diseases. The company’s flagship product, Leqembi® (lecanemab), is the world's first drug proven to slow the progression of Alzheimer's disease and reduce cognitive impairment. Leqembi has been developed in collaboration with BioArctic’s partner Eisai, who are responsible for the drug’s global regulatory interactions and commercialization.
The company’s research portfolio includes antibodies targeting Parkinson’s-related diseases, ALS, and additional projects against Alzheimer’s disease. BioArctic utilizes its proprietary BrainTransporter™ technology to enhance the efficacy of treatments by actively transporting therapies across the blood-brain barrier. This technology has the potential to significantly improve the delivery and effectiveness of treatments for a range of neurological conditions.